Chances are you haven’t heard much about lipoprotein lipase deficiency (LPLD), a disease that leads to pancreatitis. This rare disease, however, is at the center of world-changing medical advances.
Last week the European Union approved a gene therapy treatment for LPLD–and this marks the first time any medical treatment that rewrites a patients’ DNA has been approved for commercial use.
The treatment, called Glybera, will be released by Dutch firm uniQure in the second half of 2013. Glybera will be administered to patients by specially trained doctors at a limited number of European hospitals. Patients receiving treatment have their DNA altered by a series of injections into their leg muscles, which helps normalize the metabolism of fat particles carried in the blood. LPLD prevents sufferers from properly metabolizing these particles, leading to a host of side effects including pancreatitis.
Have an amazing project to share? The Electronics Show and Tell is every Wednesday at 7:30pm ET! To join, head over to YouTube and check out the show’s live chat and our Discord!
Python for Microcontrollers – Adafruit Daily — Python on Microcontrollers Newsletter: A New Arduino MicroPython Package Manager, How-Tos and Much More! #CircuitPython #Python #micropython @ThePSF @Raspberry_Pi
EYE on NPI – Adafruit Daily — EYE on NPI Maxim’s Himalaya uSLIC Step-Down Power Module #EyeOnNPI @maximintegrated @digikey
They have to extremely careful with these treatments. Past attempts to treat other diseases produced cancers in most patients when the introduced sequences landed in oncogenic-inducing regions of their genomes.
They have to extremely careful with these treatments. Past attempts to treat other diseases produced cancers in most patients when the introduced sequences landed in oncogenic-inducing regions of their genomes.